1776112-90-3 Usage
Description
N-((3R,4R)-4-fluoro-1-(6-((3-methoxy-1-methyl-1H-pyrazol-4-yl)amino)-9-methyl-9H-purin-2-yl)pyrrolidin-3-yl)acrylamide is a complex organic compound with a unique molecular structure. It is characterized by its fluorinated pyrrolidine and acrylamide moieties, as well as its purine-based core structure. N-((3R,4R)-4-fluoro-1-(6-((3-methoxy-1-methyl-1H-pyrazol-4-yl)amino)-9-methyl-9H-purin-2-yl)pyrrolidin-3-yl)acrylamide has been synthesized with specific stereochemistry, which may contribute to its potential biological activities and applications.
Uses
Used in Pharmaceutical Industry:
N-((3R,4R)-4-fluoro-1-(6-((3-methoxy-1-methyl-1H-pyrazol-4-yl)amino)-9-methyl-9H-purin-2-yl)pyrrolidin-3-yl)acrylamide is used as an antineoplastic agent for targeting the epidermal growth factor receptor (EGFR) mutant form T790M. Its application is based on its ability to inhibit the growth and proliferation of cancer cells that express this specific EGFR mutation, which is often associated with resistance to standard EGFR inhibitors.
The compound's antineoplastic activity is attributed to its interaction with the EGFR T790M mutation, which is a common resistance mechanism in non-small cell lung cancer (NSCLC) patients treated with first-generation EGFR inhibitors. By targeting this mutation, N-((3R,4R)-4-fluoro-1-(6-((3-methoxy-1-methyl-1H-pyrazol-4-yl)amino)-9-methyl-9H-purin-2-yl)pyrrolidin-3-yl)acrylamide may help overcome resistance and improve treatment outcomes for patients with EGFR T790M-positive tumors.
Furthermore, the compound's oral bioavailability suggests that it can be administered conveniently, potentially improving patient compliance and quality of life. Its development and optimization in the pharmaceutical industry may lead to new treatment options for patients with EGFR T790M-mutated cancers, offering a promising avenue for cancer research and therapeutic intervention.
Check Digit Verification of cas no
The CAS Registry Mumber 1776112-90-3 includes 10 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 7 digits, 1,7,7,6,1,1 and 2 respectively; the second part has 2 digits, 9 and 0 respectively.
Calculate Digit Verification of CAS Registry Number 1776112-90:
(9*1)+(8*7)+(7*7)+(6*6)+(5*1)+(4*1)+(3*2)+(2*9)+(1*0)=183
183 % 10 = 3
So 1776112-90-3 is a valid CAS Registry Number.
1776112-90-3Relevant articles and documents
Discovery of N-((3R,4R)-4-Fluoro-1-(6-((3-methoxy-1-methyl-1H-pyrazol-4-yl)amino)-9-methyl-9H-purin-2-yl)pyrrolidine-3-yl)acrylamide (PF-06747775) through Structure-Based Drug Design: A High Affinity Irreversible Inhibitor Targeting Oncogenic EGFR Mutants
Planken, Simon,Behenna, Douglas C.,Nair, Sajiv K.,Johnson, Theodore O.,Nagata, Asako,Almaden, Chau,Bailey, Simon,Ballard, T. Eric,Bernier, Louise,Cheng, Hengmiao,Cho-Schultz, Sujin,Dalvie, Deepak,Deal, Judith G.,Dinh, Dac M.,Edwards, Martin P.,Ferre, Rose Ann,Gajiwala, Ketan S.,Hemkens, Michelle,Kania, Robert S.,Kath, John C.,Matthews, Jean,Murray, Brion W.,Niessen, Sherry,Orr, Suvi T. M.,Pairish, Mason,Sach, Neal W.,Shen, Hong,Shi, Manli,Solowiej, James,Tran, Khanh,Tseng, Elaine,Vicini, Paolo,Wang, Yuli,Weinrich, Scott L.,Zhou, Ru,Zientek, Michael,Liu, Longqing,Luo, Yiqin,Xin, Shuibo,Zhang, Chengyi,Lafontaine, Jennifer
, p. 3002 - 3019 (2017/04/24)
Mutant epidermal growth factor receptor (EGFR) is a major driver of non-small-cell lung cancer (NSCLC). Marketed first generation inhibitors, such as erlotinib, effect a transient beneficial response in EGFR mutant NSCLC patients before resistance mechani
